Research programme: cancer and influenza virus vaccines - Etubics

Drug Profile

Research programme: cancer and influenza virus vaccines - Etubics

Alternative Names: Breast cancer vaccine - Etubics; ETBX 051; ETBX 061; Head and neck cancer vaccine - Etubics; HER vaccine - Etubics; HPV-H&N cancer vaccine - Etubics; PSA-targeted vaccine - Etubics; WT-1-targeted vaccine - Etubics

Latest Information Update: 01 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Etubics Corporation
  • Class Antineoplastics
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Influenza virus infections; Malignant melanoma
  • No development reported Breast cancer; Head and neck cancer; Prostate cancer

Most Recent Events

  • 29 Jun 2017 NantCell plans the phase Ib/II QUILT-3.051 trial for Ovarian cancer (Combination therapy, Second-line therapy or greater) in September 2017 (NCT03197584)
  • 20 Jun 2017 NantCell plans the phase Ib/II QUILT-3.048 trial for ETBX 051 and ETBX 061 in Urogenital cancer (Second-line therapy or greater, Combination therapy) (NCT03197571)
  • 02 Jun 2017 NantCell plans the phase Ib/II QUILT-3.044 trial of ETBX 051 and ETBX 061 for Non-small cell lung cancer (Combination therapy, Second-line therapy or greater) (NCT03169738)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top